CN1154491C - 用于改善替普拉那维的药物动力学的方法 - Google Patents

用于改善替普拉那维的药物动力学的方法 Download PDF

Info

Publication number
CN1154491C
CN1154491C CNB998123587A CN99812358A CN1154491C CN 1154491 C CN1154491 C CN 1154491C CN B998123587 A CNB998123587 A CN B998123587A CN 99812358 A CN99812358 A CN 99812358A CN 1154491 C CN1154491 C CN 1154491C
Authority
CN
China
Prior art keywords
tipranavir
ritonavir
bid
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB998123587A
Other languages
English (en)
Chinese (zh)
Other versions
CN1324237A (zh
Inventor
J・J・菲瑞
J·J·菲瑞
鲍德温
J·R·鲍德温
柏林
M·T·柏林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of CN1324237A publication Critical patent/CN1324237A/zh
Application granted granted Critical
Publication of CN1154491C publication Critical patent/CN1154491C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB998123587A 1998-11-04 1999-10-29 用于改善替普拉那维的药物动力学的方法 Expired - Lifetime CN1154491C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04
US60/106,963 1998-11-04

Publications (2)

Publication Number Publication Date
CN1324237A CN1324237A (zh) 2001-11-28
CN1154491C true CN1154491C (zh) 2004-06-23

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998123587A Expired - Lifetime CN1154491C (zh) 1998-11-04 1999-10-29 用于改善替普拉那维的药物动力学的方法

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ATE381922T1 (de) * 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP1575595A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim International GmbH Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US20050020517A1 (en) * 2002-12-16 2005-01-27 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of HIV infection through combined administration of tipranavir and capravirine
WO2004087139A1 (en) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
CA2583187A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
CA2585663A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
JP2008521898A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ８７３１４０を共に投与することを含むｈｉｖ感染症の治療方法
US20060142344A1 (en) * 2004-12-01 2006-06-29 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW695634
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
BR112012024522A2 (pt) * 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
CN104160274A (zh) * 2011-05-30 2014-11-19 奥德特里克公司 通过照护点药物动力学曲线分析进行治疗药物监测和投配的方法与组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
MY118526A (en) 2004-11-30
PE20001296A1 (es) 2000-11-23
US6147095A (en) 2000-11-14
CO5160321A1 (es) 2002-05-30
CN1324237A (zh) 2001-11-28
AU762349B2 (en) 2003-06-26
JP2002528502A (ja) 2002-09-03
EP1126847A1 (en) 2001-08-29
CA2346131C (en) 2013-01-15
HK1040625B (zh) 2005-04-01
TW580387B (en) 2004-03-21
AU1440400A (en) 2000-05-22
WO2000025784A1 (en) 2000-05-11
HK1040625A1 (en) 2002-06-21
CA2346131A1 (en) 2000-05-11
BR9914940A (pt) 2001-07-10

Similar Documents

Publication Publication Date Title
CN1154491C (zh) 用于改善替普拉那维的药物动力学的方法
CN1290500C (zh) 逆转录病毒蛋白酶抑制剂的联合
HUP0103319A2 (hu) Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
CN1956720A (zh) 治疗hiv感染的联合药物
WO2015022351A1 (en) Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
Adamson et al. Recent progress in antiretrovirals–lessons from resistance
WO2010099169A2 (en) A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
MX2012011415A (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
WO2015120057A1 (en) Pharmaceutical combinations against co-infection with hiv and tuberculosis
Kubin et al. Antiretroviral agents
Pandey Raltegravir in HIV-1 infection: safety and efficacy in treatment-naive patients
Fujiwara et al. Thiadiazole Derivatives: Highly Potent and Selective Inhibitors of Human Immunodeficiency Virus Type 1 (HIV‐1) Replications In Vitro
CN1285747A (zh) 艾滋病治疗用组合疗法
EP1712231A2 (en) Method for improving the pharmacokinetics of tipranavir
US20050049242A1 (en) Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
KR101924299B1 (ko) 염화세틸피리디늄의 항 hbv 바이러스 용도
US20160206645A1 (en) Combination therapies for treatment of hcv
US20230181598A1 (en) FORMULATIONS AND METHODS OF TREATING COVID-19 AND PREVENTING INFECTION WITH SARS-CoV-2
Rawlins et al. Saquinavir
WO2019246545A1 (en) Small-molecule hiv-1 capsid protein inhibitors and methods using same
WO2006095624A1 (ja) プロテアーゼインヒビター
CN112107571A (zh) 巨大戟二萜醇类化合物及其衍生物在抗hiv治疗上的应用
CN1901914A (zh) 利用氯喹和蛋白酶抑制剂的组合物治疗hiv或疟疾的方法
CN1565442A (zh) 消旋去甲胡桐素a制备抗艾滋病毒类药物的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1040625

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20040623

CX01 Expiry of patent term